JP2008530100A - 視覚障害の治療方法 - Google Patents
視覚障害の治療方法 Download PDFInfo
- Publication number
- JP2008530100A JP2008530100A JP2007555184A JP2007555184A JP2008530100A JP 2008530100 A JP2008530100 A JP 2008530100A JP 2007555184 A JP2007555184 A JP 2007555184A JP 2007555184 A JP2007555184 A JP 2007555184A JP 2008530100 A JP2008530100 A JP 2008530100A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- acid
- administering
- visual impairment
- retinal degeneration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
本願は、本明細書中にその全体が参考文献として援用されている、2005年2月10日出願の米国仮特許出願第60/651,729号の利益を請求する。
本発明は、視覚障害の治療方法を提供する。例示的な視覚障害は、黄斑変性症、網膜色素変性症、緑内障、及び/又は網膜変性症を含む。
本発明は、黄斑変性症、網膜色素変性症、緑内障、網膜変性症(例えば、桿状体光受容器変性症)を含む視覚障害の治療を含む方法を提供する。
我々は、網膜変性症の動物モデル(P23Hラット)における感覚網膜変性の抑制のための胆汁酸(タウロウルソデオキシコール酸、TUDCA)の使用を研究した。
Claims (12)
- 視覚障害の治療方法であって、親水性の胆汁酸、その塩、そのアナログ、又はその組み合わせからなる群から選ばれる化合物を対象に投与することを含む、前記方法。
- 前記親水性の胆汁酸が、ウルソデオキシコール酸である、請求項1に記載の方法。
- 投与される前記化合物が、グリコール−又はタウロ−ウルソデオキシコール酸である、請求項1に記載の方法。
- 前記視覚障害が、黄斑変性症、色素網膜変性症、緑内障、及び/又は網膜変性症である、請求項1に記載の方法。
- 対象への投与が、親水性の胆汁酸、その塩、そのアナログ、又はその組み合わせを該対象の目と接触させることを含む、請求項1に記載の方法。
- 前記化合物が医薬として許容可能な担体とともに投与される、請求項1に記載の方法。
- 投与が、腸管外に投与することを含む、請求項1に記載の方法。
- 投与が、点眼薬中の前記化合物を投与することを含む、請求項1に記載の方法。
- 視覚障害の治療方法であって、以下の:
親水性の胆汁酸、その塩、そのアナログ、又はその組み合わせからなる群から選ばれる化合物と対象の目を接触させることを含み、
ここで、該視覚障害が、黄斑変性症、色素網膜変性症、緑内障、及び/又は網膜変性症である、前記方法。 - 前記親水性の胆汁酸が、ウルソデオキシコール酸である、請求項9に記載の方法。
- 投与される前記化合物が、グリコール−又はタウロ−ウルソデオキシコール酸である、請求項9に記載の方法。
- 投与が、点眼薬中の前記化合物を投与することを含む、請求項9に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65172905P | 2005-02-10 | 2005-02-10 | |
PCT/US2006/004394 WO2006086452A1 (en) | 2005-02-10 | 2006-02-08 | Methods for treating visual disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008530100A true JP2008530100A (ja) | 2008-08-07 |
JP2008530100A5 JP2008530100A5 (ja) | 2009-04-23 |
Family
ID=36602737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007555184A Withdrawn JP2008530100A (ja) | 2005-02-10 | 2006-02-08 | 視覚障害の治療方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20080194531A1 (ja) |
EP (1) | EP1871385A1 (ja) |
JP (1) | JP2008530100A (ja) |
KR (1) | KR20080012258A (ja) |
WO (1) | WO2006086452A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021143192A (ja) * | 2017-02-09 | 2021-09-24 | アミコゲン ファーマ インコーポレイテッド | ウルソデオキシコール酸を含有する視覚障害の予防または治療用組成物 |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013025840A1 (en) * | 2011-08-15 | 2013-02-21 | Massachusetts Eye And Ear Infirmary | Methods for preserving photoreceptor cell viability following retinal detachment |
US9872865B2 (en) | 2013-03-24 | 2018-01-23 | Amylyx Pharmaceuticals Inc. | Compositions for improving cell viability and methods of use thereof |
RU2016102092A (ru) * | 2013-07-01 | 2017-08-04 | Брускеттини С.Р.Л. | Тауроурсодезоксихолевая кислота (tudca) для применения в лечении нейродегенеративных нарушений |
JP6403217B2 (ja) | 2013-07-30 | 2018-10-10 | 京都府公立大学法人 | 角膜内皮ecm治療薬 |
JPWO2015064768A1 (ja) * | 2013-10-31 | 2017-03-09 | 京都府公立大学法人 | 角膜内皮の小胞体細胞死関連疾患治療薬 |
CN104083381A (zh) * | 2014-07-29 | 2014-10-08 | 上海中医药大学 | 熊去氧胆酸的医药用途 |
KR20180029317A (ko) * | 2016-09-12 | 2018-03-21 | 경상대학교산학협력단 | 간손상 예방, 개선 또는 치료용 조성물 |
KR20180036580A (ko) | 2016-09-30 | 2018-04-09 | 주식회사 유스바이오팜 | 수가용화(水加溶化)된 우르소데옥시콜산을 함유하는 염증성 피부질환 또는 중증 소양증 예방 또는 치료용 조성물 |
WO2018147685A1 (ko) * | 2017-02-09 | 2018-08-16 | 주식회사 유스바이오팜 | 우르소데옥시콜산을 함유하는 시각장애 예방 또는 치료용 조성물 |
EP3860703A1 (en) | 2018-10-01 | 2021-08-11 | Biovisics Medical, Inc. | System and methods for controlled electrical modulation for vision therapy |
US11305118B2 (en) | 2018-11-30 | 2022-04-19 | Biovisics Medical, Inc. | Head worn apparatuses for vision therapy |
US11471680B2 (en) | 2019-04-10 | 2022-10-18 | Biovisics, Inc. | Systems and interfaces for ocular therapy |
EP3983055A1 (en) | 2019-06-14 | 2022-04-20 | Biovisics Medical, Inc. | Wearable medical device |
US12023498B2 (en) | 2019-07-12 | 2024-07-02 | Biovisics Medical, Inc. | Ocular therapy modes and systems |
US11583542B2 (en) | 2019-12-16 | 2023-02-21 | Amylyx Pharmaceuticals, Inc. | Compositions of bile acids and phenylbutyrate compounds |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69230131T2 (de) * | 1991-07-03 | 2000-03-02 | Otsuka Pharmaceutical Co., Ltd. | Apoptoseregulator |
US5656725A (en) * | 1995-05-12 | 1997-08-12 | Apoptosis Technology, Inc. | Peptides and compositions which modulate apoptosis |
US6544972B1 (en) * | 1997-09-25 | 2003-04-08 | Regents Of The University Of Minnesota | Methods of limiting apoptosis of cells |
WO1999043336A1 (en) * | 1998-02-27 | 1999-09-02 | Nutramax Laboratories, Inc. | L-ergothioneine, milk thistle, and s-adenosylmethionine for the prevention, treatment and repair of liver damage |
US20030044413A1 (en) * | 2000-08-15 | 2003-03-06 | Regents Of The University Of Minnesota | Methods of limiting apoptosis of cells |
CA2445091A1 (en) * | 2000-12-13 | 2002-06-20 | Janos Feher | Pharmaceutical compositions for treatment of digestive disorders and associated diseases |
EP1425020A4 (en) * | 2001-08-20 | 2005-05-18 | Tatton Technologies Llc | METHOD AND COMPOSITIONS FOR TREATING APOPTOSIS-RELATED DISEASES |
US20060135494A1 (en) * | 2002-11-07 | 2006-06-22 | Steer Clifford J | Methods of treating injuries of the nervous system associated with hemorrhage |
US20060204481A1 (en) * | 2003-04-02 | 2006-09-14 | Steer Clifford J | Methods of promoting cell viability |
US20060073213A1 (en) * | 2004-09-15 | 2006-04-06 | Hotamisligil Gokhan S | Reducing ER stress in the treatment of obesity and diabetes |
US20060063187A1 (en) * | 2004-09-15 | 2006-03-23 | Hotamisligil Gokhan S | Modulation of XBP-1 activity for treatment of metabolic disorders |
-
2006
- 2006-02-08 KR KR1020077020696A patent/KR20080012258A/ko not_active Application Discontinuation
- 2006-02-08 JP JP2007555184A patent/JP2008530100A/ja not_active Withdrawn
- 2006-02-08 US US11/883,977 patent/US20080194531A1/en not_active Abandoned
- 2006-02-08 WO PCT/US2006/004394 patent/WO2006086452A1/en active Application Filing
- 2006-02-08 EP EP06720482A patent/EP1871385A1/en not_active Withdrawn
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021143192A (ja) * | 2017-02-09 | 2021-09-24 | アミコゲン ファーマ インコーポレイテッド | ウルソデオキシコール酸を含有する視覚障害の予防または治療用組成物 |
Also Published As
Publication number | Publication date |
---|---|
US20080194531A1 (en) | 2008-08-14 |
KR20080012258A (ko) | 2008-02-11 |
EP1871385A1 (en) | 2008-01-02 |
WO2006086452A1 (en) | 2006-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008530100A (ja) | 視覚障害の治療方法 | |
JP2008530100A5 (ja) | ||
US20220184057A1 (en) | Combination treatment of ocular inflammatory disorders and diseases | |
JP7335795B2 (ja) | 薬学的組成物、および1,2,4-オキサジアゾール安息香酸の塩 | |
US20180092882A1 (en) | Compositions and methods for the treatment of macular degeneration | |
JP5661900B2 (ja) | アルコール摂取症状を軽減するための方法 | |
KR102382077B1 (ko) | 우르소데옥시콜산을 함유하는 시각장애 예방 또는 치료용 조성물 | |
AU2006304553A1 (en) | Method for treating primary and secondary forms of glaucoma | |
US11654140B2 (en) | Treatment of ocular inflammatory diseases using laquinimod | |
JP2013527222A (ja) | 神経保護性および網膜保護性医薬であるn−アセチル−dl−ロイシン | |
CN114053407B (zh) | 一种通过调节眼巩膜脂代谢来抑制近视的应用 | |
Drenser et al. | Crystalline retinopathies | |
CN102526006B (zh) | 单羧酸和二羧酸的酰胺化物在肾病治疗中的应用 | |
WO2005079792A1 (ja) | 重症糖尿病網膜症の予防又は治療剤 | |
US11642350B2 (en) | Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient | |
TWI815423B (zh) | 用於治療近視的方法和藥物組合物 | |
EP4087533B1 (en) | Soluble melatonin tripartate adduct for the prevention and treatment of rare and severe eye sight-threatening conditions and neuro-ophthalmic disorders | |
KR20150058159A (ko) | 바클로펜 및 아캄프로세이트 기반 황반 변성 장애의 치료 | |
US20200281928A1 (en) | Vitamin b1 in high doses for use in the medical treatment of motor symptoms of some sporadic neurodegenerative diseases, of genetic origin, and of cluster headache and of migraine headache | |
JP7427308B2 (ja) | 網膜の神経細胞の保護剤 | |
US9114120B2 (en) | Therapeutical method for the treatment of the Leber optic neuropathy | |
Garrigue et al. | A comparative study of latanoprost-cationic emulsion (Catioprost) and latanoprost aqueous solution (Xalatan) in preclinical efficacy and safety models | |
Bos | Current treatment of atopic dermatitis | |
WO2007013591A1 (ja) | ゲル状組成物を用いた後眼部組織への非侵襲性ドラッグデリバリーシステム | |
WO2005039594A1 (en) | Combinations comprising ampa receptor antagonists for the treatment of myopia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090206 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090206 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090303 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20110225 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20110225 |